TrialThe Lancet. Haematology2024

Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.

Banu Aygun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.